Eupraxia Pharmaceuticals reports new RESOLVE Phase 1b/2a symptom response data
Eupraxia Pharmaceuticals (EPRX) reports symptom response data from its ongoing Phase 1b/2a RESOLVE trial, including new data on odynophagia in eosinophilic esophagitis patients.
Story updates
12:10:20 PM UTC
SquawkNews
EPRX Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.